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I. INTRODUCTION
After receiving a testicular cancer diagnosis in 2012, Russell “Rusty” 
Williams, a West Virginia native, turned to cannabis to alleviate the crippling 
side effects of chemotherapy.1 Rusty, like other chemotherapy patients,2 found 
that cannabis helped to alleviate the pain and nausea that inevitably accompanies 
chemotherapy. Frustrated by his home state’s intolerance of the medicine that 
Rusty claims saved his life, Rusty began working as a medical cannabis advocate 
to lobby for a change in West Virginia cannabis law.3 His efforts helped realize 
his goal and real legislative change occurred. Rusty now serves as a patient 
advocate on the state’s Medical Cannabis Advisory Board where he encourages 
broader cannabis access, increased local business opportunities, and cannabis 
decriminalization.4 
With the passage of the Medical Cannabis Act (“the Act”) in 2017, West 
Virginia joined 32 states and the District of Columbia in allowing for the use of 
medical cannabis under state law.5 This Act marked a dramatic shift in the legal 
status of medical cannabis under state law. Passage of the Act was illustrative of 
the changing public perception and increasing support for cannabis.6 However, 
despite national public support in favor of legalized cannabis, West Virginia’s 
Medical Cannabis Act remains in contravention to federal laws strictly 
prohibiting cannabis possession.7 Likely thanks in large part to historical state 
and current federal prohibition, state-sanctioned medical cannabis laws each 
have unique constructions.8 West Virginia’s Medical Cannabis Act is no 
exception and was the subject of much debate and alteration prior to passage.9 
1  Egill Karlsson, Russell “Rusty” Williams on Legalization of Medical Marijuana in West 
Virginia, VIMEO (July 4, 2017), https://vimeo.com/224157914. 
2  See Cheyann Shaw, I Tried Medical Cannabis During Chemo, and Here’s What Happened, 
HEALTHLINE (Jan. 24, 2018), https://www.healthline.com/health/ovarian-cancer/medical-
cannabis-helped-me-beat-cancer#1. 
3  See Alexandra Gallo, The Foundation to Build a Proper Medical Cannabis Program in WV, 
W. VA. CITIZEN ACTION GROUP (Jan. 15, 2018), https://wvcag.org/a-proper-medical-cannabis-
program-in-wv/.
4  Id. 
 5  See State Medical Marijuana Laws, NAT’L CONF. ST. LEGISLATURES (July 2, 2019), 
http://www.ncsl.org/research/health/state-medical-marijuana-laws.aspx. 
6  Justin McCarthy, Record-High Support for Legalizing Marijuana Use in U.S., GALLUP (Oct. 
25, 2017), https://news.gallup.com/poll/221018/record-high-support-legalizing-marijuana.aspx. 
7  See 21 U.S.C.A. § 812 (West 2018). 
8  State Medical Marijuana Laws, supra note 5. 
 9  See Jake Zuckerman, Time Runs Out on Making Changes to WV’s Medical Cannabis 
Program, CHARLESTON GAZETTE-MAIL (Mar. 10, 2018), 
https://www.wvgazettemail.com/news/legislative_session/time-runs-out-on-bill-making-changes-
to-wv-s/article_a1bbc4e8-eff5-5c0d-aef0-c5c852755ba9.html. 
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This Note will argue that reducing unnecessary restrictions and allowing 
medical cannabis in its dry leaf form will better serve patients by reducing 
financial barriers erected by the Act’s strict regulations, thereby increasing 
patient access. This Note will further argue that increasing patient access should 
have additional social benefits such as boosting the economy while lessening the 
prevalence of the cannabis black market. Part I will examine the broad cannabis 
landscape including medical efficacy, brief history, and current policy and 
economic considerations associated with the budding cannabis industry. Part II 
will summarize the current provisions of West Virginia’s Medical Cannabis Act. 
Part III will compare West Virginia’s medical cannabis law and policies with 
those of other states that have comprehensive medical cannabis programs. Part 
IV will conclude by arguing that dry leaf prohibition and other restrictions are 
based on unfounded and outdated fears and that West Virginia patients and 
residents alike will be better served by provisions allowing dry leaf dispersion, 
which encourage a more robust medical market. 
II. SUMMARY OF THE CURRENT AND HISTORICAL CANNABIS LANDSCAPE
Historically, cannabis was regarded as medicinal. Cannabis was used for 
a variety of ailments in Ancient Egypt and appears in the oldest known Chinese 
pharmacopeia.10 Cannabis was even recognized as a medicine in the United 
States pharmacopeia in the 19th century.11 Cannabis did not gain its nefarious 
reputation in the United States until early in the 20th century when it began to be 
associated with Mexican immigrants and the Mexican Revolution, thus 
encouraging the popularization of the term “marijuana.”12 Nationwide 
prohibition soon followed.13 
In the modern era, California led the way for state-sanctioned medical 
cannabis programs in 1996 with a voter-approved ballot initiative that allowed 
for medical cannabis use under state law.14 However, the initial program did not 
have a state-licensing mechanism, which led to differential enforcement of the 
laws and an unregulated “gray” market for medical cannabis.15 Colorado was the 
first state to commercialize medical cannabis access in 2009 with the adoption 
of a state-licensed dispensary system.16 Since then, research into the 
effectiveness and potential negative consequences of using medical cannabis has 
exploded, prompting the National Academies of Sciences, Engineering, and 
10  STEVE DEANGELO, THE CANNABIS MANIFESTO: A NEW PARADIGM FOR WELLNESS 42 (2015). 
11  Id. at 19. 
12  Id. at 21. 
13  See infra text accompanying note 71. 
14  State Medical Marijuana Laws, supra note 5. 
15  DEANGELO, supra note 10, at 93–94. 
16  Id. at 105–07. 
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Medicine to report on a review of over 10,000 scientific abstracts from marijuana 
health research.17 Despite the significant pool of research examined in making 
the report, the Academy has concluded that cannabis research requires additional 
support and improvement, thanks in large part to the federal barriers impeding 
research.18 
A. Cannabis Has the Medical Potential to Mitigate the Effects of the Opioid
Crisis and Provide Treatment and Alternative Therapy for a Variety of
Ailments
Despite federal barriers to research, the cannabis plant’s medical 
efficacy has been substantially supported by science. In the 1990s, thanks in part 
to cannabis, scientists discovered a previously unknown cellular communication 
network in the body called the endocannabinoid system.19 The endocannabinoid 
system regulates other critical biological systems, including the “central nervous 
system, the autonomic nervous system, the endocrine network, the immune 
system, the gastrointestinal tract, the reproductive system, and 
microcirculation.”20 Thus, “if properly activated, the [endocannabinoid system] 
is capable of suppressing numerous cancers and may be protective against 
Alzheimer’s disease.”21 The endocannabinoid system also “strengthens our 
nervous and immune systems, initiates pain control, and calms inflammation.”22 
17  See NAT’L ACADS. OF SCIS., ENG’G, & MED., THE HEALTH EFFECTS OF CANNABIS AND
CANNABINOIDS: THE CURRENT STATE OF EVIDENCE AND RECOMMENDATIONS FOR RESEARCH 4 
(2017). 
18  Id. at 395–401. Thanks to the federal prohibition of cannabis and the plant’s status as a 
Schedule I drug, researchers face a myriad of regulatory, access, and funding barriers when 
attempting to conduct cannabis research. Potential researchers must apply for the opportunity to 
conduct cannabis research with the National Institute on Drug Abuse (“NIDA”), the U.S. Food and 
Drug Administration (“FDA”), and the U.S. Drug Enforcement Administration (“DEA”). The 
NIDA mission is to advance science on the causes and consequences of drug addiction, rather than 
to investigate the therapeutic potential of a particular drug. The DEA imposes strict regulations 
such as onsite security inspections and a mandate requiring as few employees handling the 
cannabis as possible, in order to prevent cannabis diversion. Federal cannabis supplied for research 
is sourced exclusively from the University of Mississippi and has historical been of lower potency 
and quality than products available in state markets. Additionally, edibles and concentrates are not 
typically available through federal sources. Id. at 377–93. 
19  CLINT WERNER, MARIJUANA: GATEWAY TO HEALTH 13 (2011). 
20  DEANGELO, supra note 10, at 45. 
 21  UWE BLESCHING, THE CANNABIS HEALTH INDEX: COMBINING THE SCIENCE OF MEDICAL 
MARIJUANA WITH MINDFULNESS TECHNIQUES TO HEAL 100 CHRONIC SYMPTOMS AND DISEASES 1 
(2015). 
22  Id. 
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The National Cancer Institute first reported that tetrahydrocannabinol 
(“THC”)23 inhibits the growth of lung cancer tumors and increases bone marrow 
resistance to cancer in 1975.24 Despite failed attempts by the National Institute 
on Drug Abuse to fund studies finding a causal link between cannabis and cancer, 
data continues to suggest that cannabis can be an effective treatment for 
cancer-induced symptoms or cancer treatment–induced symptoms.25 More 
controversially, some advocates claim that evidence suggests cannabis is capable 
of fighting, preventing, and inhibiting the growth of various cancers.26 However, 
even after its 1975 reporting, the National Cancer Institute remains conservative 
in its messages on cannabis, stating simply that “[c]annabinoids may have 
benefits in the treatment of cancer-related side effects,”27 but that “there is 
insufficient evidence to recommend . . . [cannabis] as a treatment for 
cancer-related symptoms . . . however, additional research is needed.”28 
The cannabis plant’s medical potential does not end with cancer 
treatment. There are also empirical indications that cannabis can be an effective 
tool for preventing and treating opiate addiction.29 The nation’s opioid crisis has 
23  “THC is the best known of the cannabinoids and is notorious for its psychoactive effects.” 
However, it is not strictly used for recreational intoxication. THC has a wide range of potential 
medical applications including providing patients with relief from insomnia, chronic pain, 
cancer-related symptoms, and PTSD. DEANGELO, supra note 10, at 44. 
24  Id. at 46. 
25  Id. at 47. 
 26  Id. The author notes the reputable institutions providing the data which supports this claim, 
including, “the University of Madrid, the British Journal of Cancer, the University of California 
San Diego, the University of South Florida, and the National Cancer Institute.” The author 
speculates that “[i]f any other substance showed the same results, hundreds of millions of dollars 
in public funding would be devoted to developing it.” Id. at 48 (“It is beyond reason that our tax 
dollars have for decades been poured into proving impossible myths about cannabis instead of 
exploring the most promising treatment for cancer ever discovered.”). Anecdotes from 
medical-cannabis consuming cancer patients supporting this claim are not difficult to find, but it 
should be noted that anecdotes are not substitutes for data that is a product of rigorous scientific 
method; for a local example, see Conor Griffith, Cannabis Legalization Encouraged During WV 
Municipal League Conference, MORGANTOWN NEWS (Aug. 9, 2018), 
https://www.wvnews.com/morgantownnews/news/cannabis-legalization-encouraged-during-wv-
municipal-league-conference/article_0b2f8782-231b-500c-b11e-5298b0673ba1.html (featuring 
an interview with a patient advocate representing the West Virginia Medical Cannabis Advisory 
Board claiming that “in 2012 cancer tried to kill me and an illegal flower stopped that from 
happening”). 
27  Cannabis and Cannabinoids (PDQ)—Health Professional Version, NAT’L CANCER INST., 
https://www.cancer.gov/about-cancer/treatment/cam/hp/cannabis-pdq (last updated July 16, 2019) 
[hereinafter Cannabis & Cannabinoids]. 
28  Id. 
29  DEANGELO, supra note 10, at 53. 
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become a commonly understood cultural fact and is responsible for more than 
130 daily overdose deaths throughout the nation.30 
THC was found to suppress “behavioral, biochemical, and molecular 
dependence in morphine-addicted rats” by the Laboratory for Physiopathology 
of Diseases of the Central Nervous System at Sorbonne University in 2009.31 
Subsequent human-subject experiments conducted by Columbia University 
found that “both heroin and cocaine addicts were more likely to adhere to their 
treatment when they used cannabis.”32 One California physician reports 
anecdotally that “[a]mazingly the effects of cannabinoids can reduce or eliminate 
the majority of symptoms of opiate withdrawal. Cannabis can reduce anxiety and 
agitation, improve sleep, and help normalize the digestive tract.”33 
Early data from states that implemented cannabis reform policies 
seemingly validated the positive impact cannabis has on opioid treatment and the 
crisis in general.34 “Cannabis access is associated with reduced rates of opioid 
use and abuse, opioid-related hospitalizations, opioid-related traffic fatalities, 
opioid-related drug treatment admissions, and opioid-related overdose deaths.”35 
These data have led commentators to suggest cannabis reform and access as a 
30  Opioid Overdose Crisis, NAT’L INST. ON DRUG ABUSE, https://www.drugabuse.gov/drugs-
abuse/opioids/opioid-overdose-crisis (last updated Jan. 2019); see also Opioid Crisis Fast Facts, 
CNN (Aug. 28, 2019, 4:15 PM), https://www.cnn.com/2017/09/18/health/opioid-crisis-fast-
facts/index.html (highlighting the increase in rates of addiction and overdose across recent decades, 
as well as the concurrent reactive increase in opioid regulation). 
31  DEANGELO, supra note 10, at 53. 
32  Id. 
33  Id. at 54. 
 34  See Paul Armentano, Studies: Marijuana Legalization Associated with Reduced Opioid 
Prescribing Trends, NORML BLOG (Apr. 2, 2018), https://blog.norml.org/2018/04/02/studies-
marijuana-legalization-associated-with-reduced-opioid-prescribing-trends/. 
35  Relationship Between Marijuana and Opioids, NORML, https://norml.org/marijuana/fact-
sheets/item/relationship-between-marijuana-and-opioids (last visited Sept. 9, 2019) (analyzing and 
citing a collection of studies from various institutions including: the University of Alabama, the 
Mental Health Clinician, Neuropsychopharmacology, Cannabis and Cannabinoid Research, 
Substance Abuse and Misuse, and the European Journal of Internal Medicine). Unfortunately, more 
recent studies have failed to replicate the promising early findings. See Chelsea L. Shover et al., 
Association Between Medical Cannabis Laws and Opioid Overdose Mortality Has Reversed Over 
Time, PNAS (June 25, 2019), https://www.pnas.org/content/116/26/12624 (finding that the data 
showing a negative association between medical cannabis laws and opioid overdose mortality from 
1999 to 2010 has actually reversed, becoming a positive association through 2017). However, 
causation cannot be equated to causation in either direction. The authors of the study “find it 
unlikely that medical cannabis—used by about 2.5% of the U.S. population—has exerted large 
conflicting effects on opioid overdose mortality. A more plausible interpretation is that this 
association is spurious.” Id. (“Research into therapeutic potential of cannabis should continue, but 
the claim that enacting medical cannabis laws will reduce opioid overdose death should be met 
with skepticism.”). Thus, this appears to be another illustration of the deficiency in cannabis 
research. See supra note 18 and accompanying text. Ultimately, as noted by the authors of the 
Shover study, cannabis’s therapeutic potential should not be discounted by these findings alone. 
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serious solution to the nation’s opioid crisis.36 However, cannabis reform 
opponents often argue that cannabis will act as a “gateway” to more destructive 
drugs37 or fear that cannabis access will simply encourage its use as an alternative 
drug.38 Further, West Virginians who oppose progressive reform are concerned 
about the addictive potential of cannabis, especially because pro-legalization 
groups have argued for years that cannabis is non-addictive.39 
However, these arguments are not well supported by our understanding 
of drug abuse or the cannabis plant specifically. First, “[t]he Institute of 
Medicine, itself a federal agency, [states]: ‘There is no evidence that marijuana 
serves as a stepping stone to other drugs on the basis of its particular 
physiological effect.’”40 Various studies have more recently supported this 
proposition by finding that factors other than cannabis’s psychoactive effect 
(such as personal predisposition, concurrent availability, and unemployment) are 
stronger explanations for the proposed “gateway effect” of cannabis.41 Second, a 
36  See Kendra Fershee, The Next Thousand-Year Flood: The Case for Federal Legalization of 
Medical Marijuana, HUFFINGTON POST (Dec. 18, 2017, 3:45 PM), 
https://www.huffingtonpost.com/entry/the-next-thousand-year-flood-the-case-for-
federal_us_5a382860e4b0578d1beb71c1 (describing the devastating effects of the opioid crisis 
and concluding that “there is one solution in particular that we West Virginians can embrace to 
turn the ship . . . nationally legalized medical marijuana”); see also Sanjay Gupta, Dr. Sanjay 
Gupta to Jeff Sessions: Medical Marijuana Could Save Many Addicted to Opioids, CNN, (Apr. 24, 
2018, 8:25 AM), https://www.cnn.com/2018/04/24/health/medical-marijuana-opioid-epidemic-
sanjay-gupta/index.html (“Cannabis . . . show[s] potential to save lives in three important ways. 
Cannabis can help treat pain, reducing the initial need for opioids . . . eas[e] opioid withdrawal 
symptoms, . . . [and] the compounds found in cannabis can heal the diseased addict’s brain, helping 
them break the cycle of addiction.”). 
37  DEANGELO, supra note 10, at 52 (“Faced with overwhelming evidence that cannabis itself 
is not addictive, prohibitionists . . . have advanced the gateway theory: that cannabis should remain 
illegal because it leads to the use of addictive drugs like heroin.”). 
38  While debating the West Virginia Medical Cannabis Act, Senator Mike Azinger voiced 
concern that “the bill will take away from the ‘fear’ and ‘mystery’ of marijuana and will encourage 
its use among the state’s youth.” See Jake Zuckerman, Time Runs Out on Bill Making Changes to 
WV’s Medical Cannabis Program, CHARLESTON GAZETTE-MAIL (Mar. 10, 2018), 
https://www.wvgazettemail.com/news/legislative_session/time-runs-out-on-bill-making-changes-
to-wv-s/article_a1bbc4e8-eff5-5c0d-aef0-c5c852755ba9.html (“We’re saying as a culture this is 
not a dangerous drug and what we’re doing is fine . . . . We know intuitively there is something to 
be afraid of.”). 
39  Erin Beck, Marijuana Arrests Make Up Majority of Drug Crimes, CHARLESTON GAZETTE-
MAIL (Sept. 1, 2014), https://www.wvgazettemail.com/news/marijuana-arrests-make-up-majority-
of-drug-crimes/article_42c24b21-2b5d-5aca-b678-70493b3aba9e.html (then-Charleston Police 
Bureau Chief of Investigative Services voicing concerns about the addictive potential of cannabis 
while referring to a Colorado doctor’s increase in marijuana addiction treatment after medical 
access was commercialized in 2009). 
40  DEANGELO, supra note 10, at 53 (quoting DIV. OF NEUROSCIENCE & BEHAV. HEALTH, INST.
OF MED., MARIJUANA AND MEDICINE: ASSESSING THE SCIENCE BASE (Janet E. Joy et al. eds., 1999)). 
41  See Ralph E. Tarter et al., Predictors of Marijuana Use in Adolescents Before and After 
Licit Drug Use: Examination of the Gateway Hypothesis, 163 AM. J. PSYCHIATRY 2134 (2006), 
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fear of replacing one drug (opioids) with another (cannabis) simply ignores the 
fact that each drug is unique, and thus a drug’s use should be assessed on the 
basis of its potential to heal and potential to harm. While cannabis’s addictive 
potential has been subject to hyperbole on both sides of the argument throughout 
its prohibition in the United States, it appears that the truth lies somewhere in the 
middle.42 Cannabis use can certainly escalate to a point that reaches a substance 
abuse disorder and disrupts an individual’s life significantly, as recognized by 
the Diagnostic and Statistical Manual of Mental Disorders43 (“DSM”), but the 
chemical dependency and withdrawal effects are far less severe than that of most 
other drugs.44 Further, contemporary discussion on addiction strongly suggests 
that environmental factors are more predictive of developing addiction and have 
a greater impact on treatment than access to drugs or the chemical makeup of the 
drugs themselves.45 
https://ajp.psychiatryonline.org/doi/abs/10.1176/ajp.2006.163.12.2134; Andrew R. Morral et al., 
Using Marijuana May Not Raise the Risk of Using Harder Drugs, RAND DRUG POL’Y RES. CTR.
(2002), https://www.rand.org/pubs/research_briefs/RB6010.html. 
42  For a brief discussion on cannabis addiction and history, see Hal Arkowitz & Scott O. 
Lilienfeld, Experts Tell the Truth About Pot, SCI. AM. (Mar. 1, 2012), 
https://www.scientificamerican.com/article/the-truth-about-pot/. 
43  AM. PSYCHIATRIC ASS’N, DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS 
509 (5th ed. 2013). 
44  See Cannabis & Cannabinoids, supra note 27 (“Although cannabinoids are considered by 
some to be addictive drugs, their addictive potential is considerably lower than that of other 
prescribed agents or substances of abuse . . . . Withdrawal symptoms . . . appear to be mild 
compared with withdrawal symptoms associated with opiates or benzodiazepines, and the 
symptoms usually dissipate after a few days.”). 
45  For a detailed discussion on the role environmental factors (such as trauma, poverty, or 
isolation) play in developing addiction, see GABOR MATÉ, IN THE REALM OF HUNGRY GHOSTS:
CLOSE ENCOUNTERS WITH ADDICTION (2010) (arguing that access to drugs alone does not cause 
addiction and that the three necessary factors for substance addiction to occur are (1) a susceptible 
organism (trauma histories are strong addiction predictors), (2) a drug with addictive potential 
(including cannabis), and (3) environmental stress); Making Sense: #142-Addiction, Depression, 
and a Meaningful Life: A Conversation with Johann Hari, SAM HARRIS (Nov. 12, 2018), 
https://samharris.org/podcasts/142-addiction-depression-meaningful-life/. Notably both sources 
discuss the 1980 “rat park” experiment in which researchers attempted to create a kind of utopia 
for the rat subjects. The rats were housed in an environment 200 times the square footage of a 
standard laboratory cage, complete with physical and social enrichment through “toys” and access 
to other rats of both sexes. The park also contained a tunnel large enough to accommodate only 
one rat with a morphine dispenser at its end. Even after dissolving morphine into a sweet liquid 
that is otherwise irresistible to rats and forcibly exposing the rats to morphine to develop a chemical 
dependence, rats in the park consistently avoided the morphine when given a choice. By contrast, 
socially isolated rats in standard laboratory cages consumed up to 20 times more morphine than 
their “rat park” counterparts. MATÉ, supra, at 145–46 (citing Bruce K. Alexander et al., Effect of 
Early and Later Colony Housing on Oral Ingestion of Morphine in Rats, 15 PHARMACOLOGY
BIOCHEMISTRY & BEHAV. 571 (1981), https://doi.org/10.1016/0091-3057(81)90211-2). 
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B. State-Level Cannabis Reform Brings Significant Economic Impact with
Only Minor Side Effects
Public debate, attention, and support regarding medical and recreational 
cannabis have also increased dramatically. According to Gallup, 66% of 
Americans now support full recreational cannabis legalization, “mark[ing] the 
third consecutive year that support on the measure has increased and established 
a new record.”46 This is up from just 34% in 2002.47 Further, the current support 
is bipartisan with 72% support from Democrats, 67% support from independents, 
and 51% support from Republicans.48 Other studies have found national public 
support in favor of medical cannabis legalization as high as 93%.49 In West 
Virginia, public support for medical cannabis is at 63%, with only 34% of West 
Virginia voters currently supporting legalizing recreational cannabis.50 Support 
for both medical and recreational cannabis in West Virginia appears to be rising 
with medical use support seeing a six-point increase and recreational use support 
seeing a 12-point increase when compared to a similar poll conducted a year 
prior.51 
Colorado and Washington made history by legalizing recreational adult 
use of cannabis in 2012.52 California, Oregon, Alaska, Nevada, Massachusetts, 
Maine, Vermont, Michigan, Illinois, and the District of Colombia have followed 
suit and legalized recreational adult use.53 Currently 33 states have 
comprehensive medical cannabis programs.54 As a result, the legal cannabis 
46  Justin McCarthy, Two in Three Americans Now Support Legalizing Marijuana, GALLUP 
(Oct. 22, 2018), https://news.gallup.com/poll/243908/two-three-americans-support-legalizing-
marijuana.aspx. 
47  Id. 
48  Id. 
 49  Press Release, Quinnipiac Univ. Poll, U.S. Voters Believe Comey More than Trump, 
Quinnipiac Univ. Poll Finds; Support for Marijuana Hits New High (Apr. 26, 2018), 
https://poll.qu.edu/images/polling/us/us04262018_ufcq23.pdf/. 
50  Wendy Holdren, Poll Reveals West Virginia Opinion on Politics, Opioids and More, REG.-
HERALD (Beckley, W. Va.) (Jan. 21, 2018), http://www.register-herald.com/health/poll-reveals-
west-virginia-opinion-on-politics-opioids-and-more/article_64fb9424-fd50-11e7-a5ae-
a3e364781757.html. 
51  Id. 
52  State Medical Marijuana Laws, supra note 5. 
 53  Id. In 2019, Illinois became the first state to legalize cannabis possession and sales 
legislatively. Most other reforms have come through ballot initiatives. See Amber Phillips, How 
Illinois Became the First State Legislature to Legalize Marijuana Sales, WASH. POST (June 4, 
2019), https://www.washingtonpost.com/politics/2019/06/04/how-illinois-became-first-state-
legislature-legalize-marijuana-sales/. 
54  State Medical Marijuana Laws, supra note 5 (even states with comprehensive medical use 
programs vary widely on regulations pertaining to dispensaries, acceptable forms of cannabis, and 
qualifying medical conditions). 
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industry has grown tremendously, with consumers spending $5.9 billion on legal 
cannabis in the United States in 2016.55 By 2021, that figure is expected to reach 
$19 billion.56 In Colorado alone, consumers have spent approximately $6.8 
billion in total cannabis (medical and recreational) sales to date,57 leading to over 
$1 billion in state tax revenue through 2019.58 
Because Colorado was one of the first states to embrace legal, 
commercialized recreational cannabis, its model has been the subject of much 
scrutiny as to its impacts on various aspects of society. One study found that as 
of October 2016, the legal cannabis industry in Colorado was responsible for 
creating 18,005 new full-time-equivalent positions and that “[b]ecause the 
industry is wholly confined within Colorado, spending on marijuana creates 
more output and employment per dollar spent than 90 percent of Colorado 
industries.”59 Colorado State University–Pueblo’s Institute of Cannabis Research 
found that the regulated and taxed industry led to a net positive impact of more 
than $35 million in Pueblo County’s local economy alone.60 
Naturally, state-sanctioned access to cannabis has raised traffic safety 
concerns.61 Legalization opponents point to rising numbers of automobile 
accidents, as well as an increase in THC-positive drivers involved in fatal 
crashes, to highlight the potential dangers associated with increased cannabis 
access.62 Proponents and cannabis industry analysts claim the increase in total 
accidents can be attributed simply to an increase in population, and that the 
increase in THC-positive drivers does not determinatively indicate impairment 
55  Avantika Chilkoti, States Keep Saying Yes to Marijuana Use. Now Comes the Federal No., 
N.Y. TIMES (July 15, 2017), https://www.nytimes.com/2017/07/15/us/politics/marijuana-laws-
state-federal.html. 
56  Id. 
 57  Marijuana Sales Reports, COLO. DEP’T REVENUE, 
https://www.colorado.gov/pacific/revenue/colorado-marijuana-sales-reports (last updated Aug. 
2019). 
58  Marijuana Tax Data, COLO. DEP’T REVENUE, 
https://www.colorado.gov/pacific/revenue/colorado-marijuana-tax-data (last updated Aug. 2019). 
59  Miles Light et. al., The Economic Impact of Marijuana Legalization in Colorado, 
MARIJUANA POL’Y GROUP (Oct. 2016), 
http://mjpolicygroup.com/pubs/MPG%20Impact%20of%20Marijuana%20on%20Colorado-
Final.pdf. 
60  Mona Zhang, Legal Marijuana Is a Boon to the Economy, Finds Study, FORBES (Mar. 13, 
2018, 5:34 PM), https://www.forbes.com/sites/monazhang/2018/03/13/legal-marijuana-is-a-boon-
to-the-economy-finds-study/#39aa9e7dee9d. 
61  See Drugged Driving: The Cannabis Conversation, COLO. DEP’T TRANSP.,
https://www.codot.gov/safety/alcohol-and-impaired-driving/druggeddriving (last visited Sept. 8, 
2019). 
62  David Migoya, Exclusive: Traffic Fatalities Linked to Marijuana Are Up Sharply in 
Colorado. Is Legalization to Blame?, DENV. POST (Aug. 25, 2017, 10:01 AM), 
https://www.denverpost.com/2017/08/25/colorado-marijuana-traffic-fatalities/. 
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because, unlike alcohol, THC in the blood does not necessarily directly correlate 
with THC-caused impairment.63 The National Highway Traffic Safety 
Administration report to Congress illustrates the complexities in regulating 
cannabis-impaired driving because of how differently the body reacts to and 
processes cannabis when compared to alcohol.64 Fatalities per mile driven, often 
a lesser-reported number, sheds some light on the debate—1.03 fatalities per 100 
million vehicle miles traveled in Colorado only rose to 1.17 vehicle fatalities 
between 2013 and 2016 as the national rate rose from 1.1 to 1.19 during the same 
period.65 
Another significant concern related to cannabis reform, either through 
recreational or medical laws, is its potential for increasing teenage use. And 
rightfully so, given most data conclusively finds that cannabis use negatively 
impacts cognitive development in the teenage brain.66 Two of the most 
63  Id. (“Unlike alcohol, THC can remain detectable in the blood stream for days or weeks, 
when any impairment wears off in a matter of hours . . . [s]o all those number[s] really tell us is 
that . . . a larger number of people are consuming cannabis and then, at some point . . . (are) driving 
a car.”). 
64  RICHARD P. COMPTON, NAT’L HIGHWAY TRAFFIC SAFETY ADMIN., MARIJUANA-IMPAIRED
DRIVING: A REPORT TO CONGRESS 5–7 (2017), 
https://www.nhtsa.gov/sites/nhtsa.dot.gov/files/documents/812440-marijuana-impaired-driving-
report-to-congress.pdf (noting that in contrast to alcohol impairment’s positive correlation with 
BAC, marijuana impairment is not significantly correlated with blood THC levels, leading to 
difficulties in policing impaired driving). Notably, the administration reported conclusively that 
marijuana consumption significantly affected psychomotor and cognitive skills necessary for 
driving. Id. at 11. However, the NHTSA’s “Crash Risk” Study, which is the first large-scale case 
control crash risk study in the United States to include drugs other than alcohol, found that drivers 
testing positive for THC did not have a statistically significant increased risk of crash involvement 
when compared to the sober control group after adjusting for demographic variables such as age, 
gender, and race or ethnicity. Id. at 26. When unadjusted for demographic variables, the THC 
positive group saw a 25% increase in crash risk. Id. at 25. By comparison, “drivers with a [breath 
alcohol concentration (“BrAC”)] of 0.05 are approximately [two] times more likely to crash than 
drivers at zero BrAC. At 0.08 BrAC, the adjusted relative risk of crashing is approximately four 
times that of drivers at zero BrAC.” Richard. P. Compton & Amy Berning, Traffic Safety Facts 
Research Note: Drug and Alcohol Crash Risk, NAT’L HIGHWAY TRAFFIC SAFETY ADMIN. (Feb. 
2015), http://www.nhtsa.gov/staticfiles/nti/pdf/812117-Drug_and_Alcohol_Crash_Risk.pdf. 
65  See NAT’L HIGHWAY TRAFFIC SAFETY ADMIN., FATALITY RATES: COLORADO, U.S. AND BEST 
STATE (2017), https://cdan.nhtsa.gov/STSI.htm# (click on Colorado). It should be noted that the 
proliferation of smart phones and a national increase in distracted driving present a potentially 
substantial confounding variable when attempting to examine accident increases attributable to 
cannabis access. See Kurt Meisinger & Scott A. Rushing, Fatal Distraction: Smartphones and 
Recent Increases in US Motor Vehicle Fatalities, 33 ON RISK 42, 49 (2017), 
https://www.rgare.com/docs/default-source/newsletters-articles/driverrisk.pdf?sfvrsn=7ea788_0. 
66  Université de Montréal, Teen Cannabis Use Is Not Without Risk to Cognitive Development, 
SCIENCEDAILY (Oct. 3, 2018), 
https://www.sciencedaily.com/releases/2018/10/181003090325.htm (citing Jean-François G. 
Morin et al., A Population-Based Analysis of the Relationship Between Substance Use and 
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significant predictors for teen use are access and perception of risk. While 
legalization may reduce teenage access by restricting the black market, it also 
tends to reduce the public’s perception of harm. Thus, legalization could both 
positively and negatively impact significant factors for predicting teen use. 
Consequently, reports on the effects of teenage consumption related to specific 
policy changes have varied widely.67 However, the National Institute on Drug 
Abuse reports that national cannabis “use declined among 8th graders and 
remains unchanged among 10th and 12th graders compared to five years ago, 
despite the changing state marijuana laws during this time period.”68 California 
also reported significant declines in teen consumption from 2015–2017, just as 
the state was on the verge of recreational legalization.69 
Unfortunately, Colorado’s crime rate has also been on an upward trend 
since the recreational market was established in 2014.70 This trend is divergent 
from the descending national crime rate, leading to substantial debate as to the 
cause of the increase.71 However, when analyzing the relationship between 
state-sanctioned cannabis and crime, it is imperative to remember that correlation 
is not causation. Accordingly, a local sheriff attributes increases in local wealth 
and transient populations that are associated with cannabis as the connection 
between cannabis and crime.72 Notably, property crime is reported as the driver 
of the increase.73 Further, it is also important to remember that the federal 
Adolescent Cognitive Development, 176 AM. J. PSYCHIATRY 98 (2019), 
https://ajp.psychiatryonline.org/doi/10.1176/appi.ajp.2018.18020202). 
67  See German Lopez, The Research Suggests Marijuana Legalization Could Lead to More 
Use, VOX (Nov. 14, 2018), https://www.vox.com/identities/2018/8/20/17938388/marijuana-
legalization-more-use (reporting three varying studies, one finding medical cannabis laws 
increasing teen dependence and not overall use, another finding medical cannabis laws increasing 
overall use for teens and adults, and the last finding no increase in teenage consumption after 
legalizing medical cannabis). 
68  Monitoring the Future Survey: High School and Youth Trends, NAT’L INST. ON DRUG
ABUSE, https://www.drugabuse.gov/publications/drugfacts/monitoring-future-survey-high-
school-youth-trends (last updated Dec. 2018). 
69  GREGORY AUSTIN ET AL., SCHOOL CLIMATE, SUBSTANCE USE, AND STUDENT WELL-BEING IN 
CALIFORNIA 2015–17 (2018), https://data.calschls.org/resources/Biennial_State_1517.pdf. 
70  See Scott McLean & Sara Weisfeldt, Colorado Governor Won’t Rule Out Banning 
Marijuana Again. Here’s Why, CNN (Apr. 20, 2018) 
https://www.cnn.com/2018/04/20/us/colorado-marijuana-and-crime/index.html. 
71  Id. 
72  Id. 
 73  Id. This logically supports the local sheriff’s assertion that increases in local wealth and 
transient population are responsible for the increase in crime. It should be further noted that while 
the rate of cannabis consumption has increased nationally since the 1990s, the rate of violent crime 
has concurrently decreased. See Crime in the United States by Volume and Rate per 100,000 
Inhabitants, 1998–2017, FED. BUREAU INVESTIGATION (2017), https://ucr.fbi.gov/crime-in-the-
u.s/2017/crime-in-the-u.s.-2017/tables/table-1; Nationwide Trends, NAT’L INST. ON DRUG ABUSE,
https://www.drugabuse.gov/publications/drugfacts/nationwide-trends (last updated June 2015). 
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cannabis prohibition and banking restrictions encourage cash transactions and 
onsite cash vaults for state-legal cannabis organizations,74 thereby increasing 
property crime risk factors in legal states. 
Cannabis reform is not strictly limited to the United States. Currently 
two countries, Uruguay75 and Canada,76 have legalized recreational cannabis 
subject to differing regulations. Two more countries, South Africa77 and 
Mexico,78 have seen recent supreme court rulings holding that total cannabis 
prohibition is unconstitutional. Many more have legalized medical cannabis in 
varying forms.79 
C. Federal Cannabis Prohibition Creates Unnecessary Uncertainty for
State Reform Efforts
Although near absolute federal prohibition remains in effect, this has not 
always been the case. Cannabis possession and use was legal in the United States 
until national policy began to shift with the passage of the Marihuana Tax Act in 
1937.80 There is some historical debate as to the policy considerations that 
motivated the 75th Congress to prohibit cannabis. Those considerations range 
from racism81 and classism to a mistake on the part of the legislators as to a 
74  “The rift between federal and state law has left banks trapped between their mission to serve 
the financial needs of their local communities and the threat of federal law enforcement action.” 
Cannabis: Bridging the Gap Between State and Federal Law, AM. BANKERS ASS’N,
https://www.aba.com/advocacy/our-issues/cannabis (last visited Sept. 8, 2019). 
75  See Malena Castaldi & Felipe Llambias, Uruguay Becomes First Country to Legalize 
Marijuana Trade, REUTERS (Dec. 10, 2013, 7:43 PM), https://www.reuters.com/article/us-
uruguay-marijuana-vote/uruguay-becomes-first-country-to-legalize-marijuana-trade-
idUSBRE9BA01520131211 (observing the legislative end to prohibition in Uruguay which allows 
purchase by Uruguay residents only). 
76  Kate Rogers, Eyes of the Global Marijuana Industry Are on Canada as It Legalizes 
Recreational Use, CNBC (Sept. 24, 2018, 2:09 PM), https://www.cnbc.com/2018/09/24/eyes-of-
the-global-marijuana-industry-are-on-canada-as-it-legalizes-recreational-use.html. 
77  Casey Quackenbush, South Africa’s Supreme Court Has Legalized the Private Use of 
Marijuana, TIME (Sept. 19, 2018), http://time.com/5400271/south-africa-legalizes-marijuana-
cannabis/ (“South Africa’s top court unanimously legalized the private use of cannabis on Tuesday, 
upholding a lower court’s decision ruling that it was ‘unconstitutional and therefore invalid’ to 
criminalize the drug . . . .”). 
78  German Lopez, Mexico Just Took a Big Step Toward Marijuana Legalization, VOX (Nov. 
1, 2018, 11:50 AM), https://www.vox.com/world/2018/11/1/18051592/mexico-marijuana-
legalization-supreme-court. 
79  Sean Williams, These 30 Countries Have Legalized Medical Marijuana in Some Capacity, 
MOTLEY FOOL (July 21, 2018, 11:41 AM), https://www.fool.com/investing/2018/07/21/these-30-
countries-have-legalized-medical-marijuan.aspx. 
80  See Becky Little, Why the U.S. Made Marijuana Illegal, HIST. (Aug. 4, 2017), 
https://www.history.com/news/why-the-u-s-made-marijuana-illegal. 
81  Id. 
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perceived (but nonexistent) difference between “marijuana” and “cannabis.”82 
Regardless, sound policy considerations appear to have been absent from the 
initial national prohibition effort. 
Increased drug use during the 1960s led to a more aggressive national 
prohibition effort.83 In 1970, Congress passed the Controlled Substances Act 
(“CSA”), which adopted harsher penalties for possession and cultivation of 
cannabis.84 Despite a 1972 report made by the National Commission on 
Marijuana and Drug Abuse that recommended decriminalization of simple 
cannabis possession,85 the strict prohibitions of the CSA have continued into the 
present. The Nixon Administration aggressively refused to consider any of the 
Commission’s recommendations in regard to cannabis.86 
Federal prohibition enforcement has become increasingly complex and 
uncertain as states continue to adopt more progressive policies, especially given 
the administrative changes following the 2016 election. In 2013, under the 
Obama Administration, Deputy Attorney General James M. Cole released a 
memorandum to U.S. Attorneys regarding enforcement of the federal cannabis 
prohibition (the “Cole Memo”).87 The Cole Memo encouraged prosecutors to 
take a hands-off approach in jurisdictions with robust medical cannabis 
regulatory schemes.88 In fact, it went as far as to claim “a robust system may 
affirmatively address [federal marijuana priorities] by . . . implementing 
effective measures to prevent diversion of marijuana outside of the regulated 
system . . . and replacing an illicit marijuana trade that funds criminal enterprises 
82  See DAVID R. FORD, MARIJUANA: NOT GUILTY AS CHARGED 64 (1997). 
 83  President Richard Nixon, Special Message to the Congress on Control of Narcotics and 
Dangerous Drugs (July 14, 1969), https://www.presidency.ucsb.edu/node/239611. 
84  21 U.S.C.A. § 841 (West 2018). 
 85  NAT’L COMM’N ON MARIHUANA & DRUG ABUSE, MARIHUANA: A SIGNAL OF 
MISUNDERSTANDING (1972), http://www.druglibrary.org/schaffer/Library/studies/nc/ncmenu.htm 
(“[T]he criminal law is too harsh a tool to apply to personal possession even in the effort to 
discourage use. It implies an overwhelming indictment of the behavior which we believe is not 
appropriate. The actual and potential harm of use of the drug is not great enough to justify intrusion 
by the criminal law into private behavior, a step which our society takes only the greatest 
reluctance.”). 
86  See Gene Weingarten, Just What Was He Smoking?, WASH. POST (Mar. 21, 2002), 
https://www.washingtonpost.com/archive/lifestyle/2002/03/21/just-what-was-he-
smoking/e984a758-94fc-482f-a9d7-890c30a41b5e/?noredirect=on&utm_term=.f828f8946a09. 
87  Memorandum from James M. Cole, Deputy Att’y Gen., for All U.S. Att’ys on Guidance 
Regarding Marijuana Enforcement (Aug. 29, 2013), 
https://www.justice.gov/iso/opa/resources/3052013829132756857467.pdf [hereinafter Cole 
Memo]. Notably, the Cole Memo was released prior to the 2014 elections in which Colorado and 
Oregon legalized recreational use. However, the Cole Memo remained in effect during the budding 
of the regulated recreational market until it was rescinded by Attorney General Jeff Sessions in 
2018. See infra text accompanying note 125. 
88  Cole Memo, supra note 87. 
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with a tightly regulated market.”89 However, in 2018, under the Trump 
Administration, Attorney General Jeff Sessions signed a memo rescinding the 
Cole Memo.90 The new guidance directs U.S. Attorneys to “follow the 
well-established principles that govern all federal prosecutions” when deciding 
which “marijuana activities to prosecute.”91 Predictably, the new direction to 
prosecutors prompted diverse commentary from legal analysts, scholars, and the 
cannabis industry.92 
A hemp93 farm in Mason County, West Virginia, provides a local 
illustration of the complexities of the federal and state cannabis law scheme. 
Prior to the recent passage of the Farm Bill, the U.S. Attorney for the Southern 
District of West Virginia filed suit against the hemp farm, alleging violations of 
the federal Controlled Substances Act due to the process by which the farm 
obtained seeds as well as intent to sell processed hemp across state lines.94 The 
defendant is licensed to grow hemp under the industrial hemp pilot program in 
89  Id. The federal marijuana priorities also include: preventing distribution to minors, 
preventing state-authorized marijuana activity from being used as a cover or pretext for the 
trafficking of other illegal drugs or activity, preventing violence and the use of firearms in the 
cultivation and distribution of marijuana, and preventing the exacerbation of other adverse public 
health consequences associated with marijuana use. Id. 
90  See Laura Jarrett, Sessions Nixes Obama-Era Rules Leaving States Alone that Legalize Pot, 
CNN (Jan. 4, 2018, 5:44 PM), https://www.cnn.com/2018/01/04/politics/jeff-sessions-cole-
memo/index.html. 
91  Memorandum from Jefferson B. Sessions, III, Att’y Gen., for All U.S. Att’ys on Marijuana 
Enforcement (Jan. 4, 2018), https://www.justice.gov/opa/press-release/file/1022196/download. 
92  See Brad Auerbach, How Cannabis Entrepreneurs Feel About the Sessions’ Reversal of the 
Cole Memo, FORBES (Mar. 3, 2018, 7:32 PM), 
https://www.forbes.com/sites/bradauerbach/2018/03/03/how-cannabis-entrepreneurs-feel-about-
sessions-reversal-of-the-cole-memo/#6ce92565c4ae (“Many observers across the political 
spectrum concur that the decision will heighten uncertainty in an industry seeking stability.”); Ilya 
Somin, Jeff Sessions Escalates the Federal War on Marijuana—and His Assault on Federalism, 
VOLOKH CONSPIRACY (Jan. 4, 2018, 9:40 PM), http://reason.com/volokh/2018/01/04/jeff-sessions-
escalates-federal-war-on-m (noting that rescission’s “impact may be relatively minor,” but calling 
it an “assault on constitutional federalism” with the potential to “have a major chilling effect” if 
even a small number of sellers are targeted); Jacob Sullum, Did Jeff Sessions’ Marijuana Memo 
Restore the Rule of Law?, REASON (Jan. 5, 2018, 3:15 PM), 
http://reason.com/blog/2018/01/05/did-jeff-sessions-marijuana-memo-restore (arguing that the 
rescission could be an appropriate response to excessive exercising of power by the Obama 
Administration). 
93  Hemp is a low-THC (less than one percent) variety of the cannabis plant. “Industrial hemp 
could be used in more than 25,000 products spanning nine markets, including agriculture, textiles, 
recycling, automotive, furniture, food/nutrition/beverages, paper, construction materials, and 
personal care . . . .” S. Con. Res. 32, 83d Leg., Reg. Sess. (W. Va. 2018) (emphasizing the 
economic importance of industrial hemp, but recognizing that Congress has “failed to amend the 
Controlled Substances Act to make clear that hemp . . . is not a controlled substance”). 
94  See United States v. Mallory, 372 F. Supp. 3d 377, 379 (S.D. W. Va. 2019). 
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West Virginia.95 Nevertheless, the court ordered a preliminary injunction 
prohibiting the transportation or sale of any processed plant but allowing the farm 
to harvest, dry, and process its crop.96 After the passage of the Farm Bill, the 
court dissolved the preliminary injunction despite the government’s last-minute 
attempt to question whether the crop at issue was in fact industrial hemp.97 West 
Virginia Commissioner of Agriculture Kent Leonhardt expressed that his office 
was “confused on why the U.S. Attorney’s Office is working so diligently to 
thwart a growing agricultural industry in the state . . . [e]specially . . . when there 
are so many other serious issues affecting West Virginia.”98 
It seems worth noting the speed with which changes in the legal cannabis 
landscape are taking place. Since early fall 2018, national public support for 
cannabis increased by two percent;99 former Attorney General Sessions was 
removed from his position by President Trump;100 the federal prohibition on 
hemp was lifted via the Farm Bill;101 and the Joint Economic Committee 
Democrats issued a report on the national cannabis economy, which advocates 
changing federal law so that states can experience the economic, medical, and 
social justice benefits of cannabis reform without federal interference.102 
Internationally, Canada’s nationwide legalization went into effect, and South 
Africa’s Supreme Court struck down blanket prohibition of personal cannabis 
use. 
95  Id. 
96  Id. at 379–80. 
 97  United States v. Mallory, No. 3:18-1289, 2019 U.S. Dist. LEXIS 10796, at *4 (S.D. W. Va. 
Jan. 23, 2019) (“If the United States truly believed the product exceeded the THC limits, it could 
have moved the Court to require testing long before now. Instead, the United States waited until 
the CAMO Defendants will face certain harm by continuing the injunction before it requested 
testing.”). 
98  Correction: BC-WV—Hemp Farm-Lawsuit Story, U.S. NEWS & WORLD REP. (Sept. 26, 
2018, 4:59 PM), https://www.usnews.com/news/best-states/west-virginia/articles/2018-09-24/us-
attorney-sues-west-virginia-hemp-farm. 
99  Compare McCarthy, supra note 6 (reporting 64% public support), with McCarthy, supra 
note 46 (reporting 66% public support). 
100  Peter Baker et al., Jeff Sessions Is Forced Out as Attorney General as Trump Installs 
Loyalist, N.Y. TIMES (Nov. 7, 2018), https://www.nytimes.com/2018/11/07/us/politics/sessions-
resigns.html. 
101  Andre Bourque, How Hemp and the Farm Bill May Change Life as You Know It, FORBES
(Dec. 17, 2018, 9:39 AM), https://www.forbes.com/sites/andrebourque/2018/12/17/how-hemp-
and-the-farm-bill-may-change-life-as-you-know-it/#31204f00694c. 
102  JOINT ECON. COMM. DEMOCRATS, THE NATIONAL CANNABIS ECONOMY (2018), 
https://www.jec.senate.gov/public/_cache/files/bf473de9-98bb-4465-a310-
de992926409a/national-cannabis-economy-final.pdf (advocating the bipartisan STATES Act, 
which would amend the Controlled Substances Act so that it would no longer apply to state-
sanctioned cannabis industries and clarify that financial transactions with state-legal cannabis 
businesses are not drug trafficking). 
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D.  West Virginia Policy Considerations Illuminate the Potential for
Medical Cannabis to Benefit the State
The local effects of the opioid crisis are likely one of those “other serious 
issues affecting West Virginia” present among Commissioner Leonhardt’s 
concerns. West Virginia communities have been hit especially hard by the opioid 
crisis.103 “In 2017, there were 833 drug overdose deaths involving opioids in 
West Virginia—a rate of 49.6 deaths per 100,000 persons. This is the double the 
rate in 2010 and threefold higher than the national rate of 14.6 deaths per 100,000 
persons.”104 Tragically, overdoses are only one of many impacts on the state due 
to the opioid crisis. Increased prevalence in injection drug use has also led to 
increased prevalence of associated diseases.105 The combined costs related to 
“fatalities, health care spending, addiction treatment, criminal justice and lost 
productivity” are estimated to have cost the state a staggering $8.72 billion in 
2016 alone.106 The lost productivity caused by the opioid crisis contributes to 
West Virginia’s very poor labor force participation rate, which as of 2016 was 
the lowest among all states at 53%.107 Not only is the participation rate poor, the 
labor pool is also gradually shrinking as West Virginia is impacted by population 
decline due to death rates exceeding birth rates coupled with an exodus from the 
state.108 
General health and wellness throughout the state is another significant 
contributing factor to West Virginia’s labor force participation rate.109 According 
to America’s Health Rankings annual 2018 report, West Virginia ranks 44th 
among the states with respect to state health scores.110 West Virginia’s cancer 
103  West Virginia Opioid Summary, NAT’L INST. ON DRUG ABUSE, 
https://www.drugabuse.gov/drugs-abuse/opioids/opioid-summaries-by-state/west-virginia-
opioid-summary (last updated Mar. 2019). 
104  Id. 
 105  Id. (reporting prevalence of HIV and hepatitis C); see also Dina Fine Maron, West Virginia 
Roiled by Side Effect of Opioid Crisis—A Major Hepatitis A Outbreak, SCI. AM. (Aug. 27, 2018), 
https://www.scientificamerican.com/article/west-virginia-roiled-by-side-effect-of-opioid-crisis-a-
major-hepatitis-a-outbreak/. 
106  Wendy Holdren, Analysis Shows Opioid Crisis Cost West Virginia More than $8.72 Billion 
in 2016, REG.-HERALD (Beckley, W. Va.) (May 4, 2018), https://www.register-
herald.com/health/analysis-shows-opioid-crisis-cost-west-virginia-more-than-
billion/article_1db033ff-73c2-5a87-a267-18b58cc41101.html. 
107  BUREAU OF BUS. & ECON. RESEARCH, W. VA. UNIV., WEST VIRGINIA ECONOMIC OUTLOOK 
2018–2022, at 1 (2017), 
https://researchrepository.wvu.edu/cgi/viewcontent.cgi?article=1003&context=bureau_be. 
108  Id. at 17. 
109  Id. at 17–18. 
 110  AM.’S HEALTH RANKINGS, ANNUAL REPORT 2018, at 19 (2018). State health scores are 
determined by examining 27 health indicators grouped into two categories: determinants of health 
and health outcomes. 
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incidence rate is above the national average,111 and research suggests that cancer 
mortality rates are disproportionately higher within rural Appalachia (including 
West Virginia) than the rest of the country.112 Sadly, these factors and many 
others have resulted in West Virginia’s consistent status as one of the poorest 
states in the country, with consistently low income and high levels of poverty.113 
To combat this fact, the West Virginia Center on Budget and Policy recommends 
increasing workforce participation (noting that criminal justice reform could 
alleviate criminal histories that are currently a significant barrier to 
employment), the general health of the workforce, and education and skills of 
the workforce (advocating for a public teacher pay raise114).115 
New FBI reporting procedures under the Trump Administration have 
made specifically tracking cannabis arrests more difficult,116 but investigative 
reporting reveals that cannabis arrests across the nation are increasing despite 
legalization and reform efforts.117 In 2012, 53% of drug arrests in West Virginia 
were for marijuana, most of which were simple possession.118 Given that the 
111  State Cancer Profiles, NAT’L CANCER INST., https://statecancerprofiles.cancer.gov/quick-
profiles/index.php?statename=westvirginia#t=2 (last visited Sept. 8, 2019). 
112  Nengliang Yao et al., Cancer Disparities in Rural Appalachia: Incidence, Early Detection, 
and Survivorship, 33 J. RURAL HEALTH 375, 375 (2018), 
https://onlinelibrary.wiley.com/doi/pdf/10.1111/jrh.12213. 
113  See W. VA. CTR. ON BUDGET & POLICY & AM. FRIENDS SERV. COMM., 2016 THE STATE OF 
WORKING WEST VIRGINIA: WHY IS WEST VIRGINIA SO POOR? 1 (2016), https://wvpolicy.org/wp-
content/uploads/2018/5/SWWV-2016-release.pdf [hereinafter WORKING WEST VIRGINIA]. 
114  In February 2018, the entire state of West Virginia experienced a public-teacher strike that 
made national news headlines. The strike was a response to a raise that teachers felt was insufficient 
to cover cost-of-living increases, as well as concerns related to public-employee insurance 
programs, health-care costs, and payroll-tax deduction options. The state superintendent of schools 
said that he recognized teachers “deserve more,” but “the economic realities of our state may not 
allow everything teachers deserve to take place immediately.” Emily Stewart, All of West 
Virginia’s Teachers Have Been on Strike for Over a Week, VOX (Mar. 4, 2018), 
https://www.vox.com/policy-and-politics/2018/3/3/17074824/west-virginia-teachers-strike-
justice-union. 
115  See WORKING WEST VIRGINIA, supra note 113. 
116  Tom Angell, Trump Administration Makes It Harder to Track Marijuana Arrests (But I Did 
It Anyway), FORBES (Sept. 25, 2017, 2:28 PM), 
https://www.forbes.com/sites/tomangell/2017/09/25/trump-administration-makes-it-harder-to-
track-marijuana-arrests-but-i-did-it-anyway/#471e4d3e68bc. 
117  Tom Angell, Marijuana Arrests Are Increasing Despite Legalization, New FBI Data Shows, 
FORBES (Sept. 24, 2018, 8:33 AM), 
https://www.forbes.com/sites/tomangell/2018/09/24/marijuana-arrests-are-increasing-despite-
legalization-new-fbi-data-shows/#67acb38d4c4b. 
118  Beck, supra note 39. Notably, a law enforcement officer interviewed within the article said 
that officers get frustrated because the penalties for cannabis possession aren’t strict enough to 
deter use: “First offense is $50 with no jail time, so it’s almost like running a red light.” However, 
currently cannabis possession laws are stricter than this would suggest, with the penalty for 
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national rate of cannabis related incarceration appears to be increasing, 
possession in West Virginia continues to be criminal. As public interest increases 
and harm perceptions change, it is likely safe to assume that cannabis related 
arrests will continue to be prominent among West Virginia drug arrests. 
III. WEST VIRGINIA MEDICAL CANNABIS ACT SUMMARY
The Act extensively regulates the emerging medical cannabis industry 
by controlling doctor recommendations and the means of growing, processing, 
and dispensing. The Act allows for doctor-recommended cannabis as treatment 
for patients’ “[s]erious medical condition[s]” including cancer, HIV, Parkinson’s 
disease, epilepsy, post-traumatic stress disorder, neuropathies, multiple sclerosis, 
Huntington’s disease, Crohn’s disease, chronic pain, and terminal illnesses.119 
Patients with a qualifying condition must apply for an identification card and 
present the identification card to an authorized dispensary in order to purchase 
medical cannabis.120 Alternatively, the patient is allowed to register a caregiver 
who is then able to apply for an identification card and purchase medical 
cannabis on behalf of the patient.121 Patients are limited to two registered 
caregivers, and caregivers are limited to acting on behalf of up to five patients.122 
Both patients and caregivers must have possession of their identification cards 
while purchasing or possessing medical cannabis.123 Identification cards for 
patients and caregivers may be suspended or revoked upon “intentionally, 
knowingly or recklessly” violating any provision of the Act.124 The suspension 
or revocation shall occur concurrently with any other criminal penalty that may 
apply.125 
A. Rules for Growing, Processing, and Dispensing
Dispensaries and patients must follow the Act’s regulations on the forms 
of cannabis that can be dispensed. Legal forms currently include pills, oils, 
possession being jail time (90 days to six months), fines up to $1,000, or both. See W. VA. CODE 
ANN. § 60A-4-401(c) (West 2019). 
119 § 16A-2-1(a)(30). The exhaustive list includes only the following: cancer, HIV,
amyotrophic lateral sclerosis, Parkinson’s disease, multiple sclerosis, damage to the nerve tissue 
of the spinal cord, epilepsy, neuropathies, Huntington’s disease, Crohn’s disease, post-traumatic 
stress disorder, intractable seizures, sickle cell anemia, chronic pain, and terminal illness. Id. 
120  Id. § 16A-5-1(a)–(c). 
121  Id. § 16A-5-1(c). 
122  Id. § 16A-3-2(a)(4)(5). 
123  Id. § 16A-3-2(a)(7). 
124  Id. § 16A-5-9. 
125  Id. 
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topical forms,126 tinctures,127 liquids, and dermal patches.128 Although the Act 
grants the Bureau for Public Health within the West Virginia Department of 
Health and Human Resources (the “Bureau”) authority to promulgate rules under 
the Act,129 the Act expressly prohibits dispensing of dry leaf cannabis and edible 
medical cannabis forms, subject to change upon the promulgation of the 
Bureau’s rules.130 
The Act delegates issuance of growing, processing, and dispensing 
permits to the Bureau. However, the approval of permits is limited by the 
following: “The [B]ureau may not issue permits to more than 10 growers . . . 
more than 10 processors . . . [and] more than 100 dispensaries.”131 Additionally, 
the following must be considered by the Bureau when issuing a permit: “(1) 
Geographic location; (2) Regional population; (3) The number of patients 
suffering from serious medical conditions; (4) The types of serious medical 
conditions; (5) Access to public transportation; (6) Approval by local health 
departments; (7) [county prohibition]; (8) Any other factor the [B]ureau deems 
relevant.”132 Although the Act initially prohibited the vertical integration of 
growers, processors, and dispensaries by mandating that “[a] grower or processor 
may not be a dispensary,”133 the legislature passed a bill in 2019 that allows for 
the vertical integration of growers and processors.134 Individuals can only 
possess one grower permit, one processor permit, or two dispensary permits.135 
The Act contains a variety of controls aimed at preventing cannabis 
diversion into illegal markets. All medical cannabis organizations must 
“implement an electronic inventory tracking system which shall be directly 
accessible to the [B]ureau through its electronic database that electronically 
tracks all medical cannabis on a daily basis.”136 For a grower or processor, this 
includes a “seed-to-sale tracking system” which tracks the entire growing 
126  Topical forms can include gels, creams, or ointments. Id. § 16A-3-2(a)(2)(C). 
 127  A tincture is a concentrated liquid herbal remedy generally consumed orally. See Cathy 
Wong, What You Need to Know About Herbal Tinctures, VERYWELL HEALTH, 
https://www.verywellhealth.com/herbal-tinctures-89393 (last updated Aug. 30, 2019). 
128 W. VA. CODE ANN. § 16A-3-2(a)(2).
129  Id. § 16A-3-1(b). 
130  Id. § 16A-3-3(b). 
131  Id. § 16A-6-13(a)(1)–(3). 
132  Id. § 16A-6-3(d)(1)–(8). 
133  Id. § 16A-6-13(a)(9) (West 2017) (amended 2019). 
 134  See S. 1037, 84th Leg., 1st Extraordinary Sess. (W. Va. 2019); Erin Beck, Lawmakers Pass 
Fix to Medical Marijuana Bill, REG.-HERALD (Beckley, W. Va.) (May 20, 2019), 
https://www.register-herald.com/news/state_region/lawmakers-pass-fix-to-medical-marijuana-
bill/article_dbad3657-ba40-546a-a599-ea6d068941b9.html. 
135 W. VA. CODE ANN. § 16A-6-13(a)(4)–(6) (West 2017) (amended 2019). Growers may have
up to two locations per permit. Id. § 16A-6-13(a)(1) (West 2019). 
136  Id. § 16A-7-1(a). 
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process through to selling to a dispensary.137 All growing must be done in “an 
indoor, enclosed, secure facility [with] . . . electronic locking systems [and] 
electronic surveillance.”138 Transporting medical cannabis must be done under 
similar regulations; the Act requires the use of GPS and electronic tracking 
systems to ensure delivery and receipt recordkeeping while defending against 
losses occurring in storage or transit.139 In addition to the security and reporting 
regulations, the Act further prevents the criminal diversion of medical cannabis 
by creating specific criminal penalties for practitioners, operators, or employees 
of medical cannabis organizations.140 The Bureau is empowered by the Act to 
“notify any appropriate law-enforcement agency of information relating to any 
violation or suspected violation of [the] [A]ct.”141 Additionally, the Bureau shall 
verify permits, registrations, or identification cards to law-enforcement 
personnel in appropriate cases.142 
Dispensaries are subject to further precautionary regulations. Initially, 
the Act required “a physician or pharmacist onsite at all times during the hours 
the dispensary is open.”143 However, this requirement was removed by the 
legislature in 2019. When dispensing to a patient or caregiver, “the dispensary 
may not dispense an amount greater than a 30-day supply until the patient has 
exhausted all but a seven-day supply.”144 A medical cannabis sale must include 
a safety insert which educates patients on “[l]awful methods for administering 
medical cannabis[,] . . . potential dangers[,] . . . [h]ow to recognize what may be 
problematic usage[,] . . . [and] [h]ow to prevent or deter the misuse of medical 
cannabis by minors or others.”145 Medical cannabis must be sold in a sealed and 
labeled package which contains health and legal warnings, as well as the 
package’s amount of individual doses and percentage of tetrahydrocannabinol 
(“THC”) and cannabidiol (“CBD”), as well as the species from which the doses 
are derived.146 
137  Id. § 16A-7-1(a)(1). 
138  Id. § 16A-7-2(b)(1). 
139  Id. § 16A-7-3. 
140  See id. §§ 16A-12-1 to -9. 
141  Id. § 16A-10-3. 
142  Id. 
143  Id. § 16A-8-1(b) (West 2017) (amended 2019). 
144  Id. § 16A-8-1(d) (West 2019). 
145  Id. § 16A-8-1(g). 
146  Id. § 16A-8-1(h). 
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B. Administrative Rules and Requirements
Common with cannabis regulations in other states, the Act contains 
specific tax provisions for medical cannabis.147 “A tax is imposed on the gross 
receipts of a grower/processor received from the sale of medical cannabis by a 
grower/processor to a dispensary, to be paid by the grower/processor, at a rate of 
ten percent.”148 This tax has to be “paid by the grower/processor and shall not be 
added as a separate charge . . . of the price paid by a dispensary, patient or 
caregiver.”149 Further, “[m]edical cannabis shall not be subject to a sales tax.”150 
The Act establishes a Medical Cannabis Program Fund to receive the taxes 
payable under the act and directs allocation of appropriated funds.151 
“Money in the fund is allocated in accordance with the following 
percentages”: 55% of the revenue in the fund shall be allocated to the Bureau 
with the remaining 45% of the revenue allocated by 50% to the Fight Substance 
Abuse Fund, 40% to the Division of Justice and Community Services (for grants 
to local law enforcement agencies for training, drug diversion, and other 
programs focused on crime and addiction), and 10% to a fund to be used for law-
enforcement professional training and professional development programs.152 
The Medical Cannabis Advisory Board, created by the Act and located 
within the Bureau, is tasked with “analyz[ing] the statutory and regulatory law 
relating to medical cannabis within the state . . . and events in other states and 
the nation with respect to medical cannabis.”153 Further, “[t]he [Board] shall” 
issue a written report to the Governor, the Senate and House of Delegates two 
years after the effective date of the Act.154 The report “shall include 
recommendations and findings as to” whether to change the types of medical 
professionals who can issue certifications to patients; whether to change, add, or 
reduce the types of qualifying medical conditions; whether to change the form of 
medical cannabis permitted; whether to change, add, or reduce the number of 
growers, processors, or dispensaries; and how to ensure affordable patient access 
to medical cannabis.155 “After receiving the report of the advisory board, at the 
discretion of the commissioner, the [B]ureau may propose rules for legislative 
promulgation . . . to effectuate recommendations made by the advisory board.”156 
147  Id. § 16A-9-1. 
148  Id. § 16A-9-1(a) (West 2017) (amended 2019). 
149  Id. 
150  Id. § 16A-9-1(d). 
151  Id. § 16A-9-2 (West 2019). 
152  Id. § 16A-9-2(c). 
153  Id. § 16A-11-1(j)(1)–(2). 
154  Id. § 16A-11-1(j)(4). 
155  Id. § 16A-11-1(j)(5)(A)–(E). 
156  Id. § 16A-11-2. 
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In addition to the Medical Cannabis Advisory Board, the Act instructs 
the Bureau to “establish and develop a research program to study the impact of 
medical cannabis on the treatment and symptom management of serious medical 
conditions.”157 The program includes “[creating] a database of all serious 
medical conditions . . . which are cited by practitioners in the certifications of 
patients.”158 Once 25 or more patients with the same serious medical condition 
are added to the database, the Bureau shall “petition the United States Food and 
Drug Administration [(“FDA”)] and the United States Drug Enforcement 
Administration [(“DEA”)] for approval to study the condition and the impact of 
medical cannabis on the condition.”159 Concurrent with the FDA and DEA 
petitions, the Bureau shall “publicly announce the formation of a research study 
to which a vertically integrated health system and a university within this state 
may submit a request to participate.”160 The Bureau must also select patients to 
participate in the research study and notify each consenting patient “where the 
patient may secure medical cannabis . . . at no cost to the patient.”161 “The cost 
of the medical cannabis which is dispensed to patients in accordance with an 
approved research study shall be paid for by the fund.”162 Further, if the FDA 
and DEA reject the proposal for the research study, the Bureau shall “take all 
reasonable steps to collect and collate data on the serious medical condition and 
the use of medical cannabis as a treatment for the serious medical condition and 
consider submitting an additional request . . . for a research study on the same 
condition.”163 “A health care medical cannabis organization may not participate 
in a research study of any kind, including the program established [by the 
Act].”164 
The Act offers specific protections for patients and caregivers with 
respect to criminal penalties and employment discrimination.165 The Act protects 
patients, caregivers, practitioners, and medical cannabis organizations from 
being arrested solely for their lawful use action taken in accordance with the 
Act.166 Employers are prohibited from discriminating or retaliating against an 
157  Id. § 16A-13-2(a). 
158  Id. § 16A-13-2(b)(2). 
159  Id. § 16A-13-2(b)(3). 
 160  Id. § 16A-13-2(b)(4). “Vertically integrated health system” is defined as “[a] health delivery 
system in which the complete spectrum of care, including primary and specialty care, 
hospitalization and pharmaceutical care, is provided within a single organization.” Id. § 16A-13-
1. 
161  Id. § 16A-13-2(b)(6). 
 162  Id. § 16A-13-2(c) (referring to the fund created by the Act which receives 55% of medical 
cannabis tax revenue). 
163  Id. § 16A-13-2(b)(7). 
164  Id. § 16A-13-6. 
165  Id. § 16A-15-4. 
166  Id. 
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employee “solely on the basis of such employee’s status as an individual who is 
certified to use medical cannabis.”167 However, the Act expressly does not 
“require an employer to make any accommodation of the use of medical cannabis 
on the property or premises of any place of employment.”168 Further, the Act “in 
no way limit[s] an employer’s ability to discipline an employee for being under 
the influence of medical cannabis in the workplace . . . when the employee’s 
conduct falls below the standard of care normally accepted for that position.”169 
C. The Medical Cannabis Advisory Board Recommends Broader
Applicability with Fewer Restrictions, Including Allowing Dry Leaf
Cannabis
Pursuant to its duty under the Act, the Medical Cannabis Advisory Board 
published a collection of findings and seven recommendations in February 
2018.170 Those recommendations include the following: Recommendation 1.1 
would “[a]mend the Act to clarify requirements and responsibilities for 
physicians who issue certifications”; Recommendation 1.2 would “[r]eplace the 
phrase ‘Serious Medical Conditions’ with the phrase ‘Medical Conditions with 
Possible Serious Manifestations’ throughout”; Recommendation 2.1 would 
“[i]nclude dry leaf or plant form medical cannabis medically appropriate for 
administration by vaporization or nebulization”; Recommendation 3.1 would 
“[r]emove limitations on the number of permits the Bureau for Public Health 
may issue for growers, processors, and dispensaries”; Recommendation 3.2 
would “[r]emove limitation that a grower or processor may not also be a 
dispensary to permit the vertical integration of growers, processors and 
dispensaries”; Recommendation 3.3 urges the legislature to “evaluate the need 
for the requirement that a physician or pharmacist must be onsite at all times 
during the hours the dispensary is open to receive patients”; and 
Recommendation 3.4 encourages authorization of “a pre-registration process for 
potential medical cannabis patients to more clearly ascertain the market interest 
within West Virginia.”171 
The legislature considered various amendments to the Act a year after 
its passage. Senate Bill 487 was considered and ultimately rejected during the 
2018 legislative session.172 The proposal would have amended the Act to allow 
dry leaf cannabis dispersion without requiring a new rule promulgated by the 
167  Id. § 16A-15-4(b)(1). 
168  Id. § 16A-15-4(b)(2). 
169  Id. 
170 W. VA. MED. CANNABIS ADVISORY BD., REPORT AND RECOMMENDATIONS 4 (2018),
https://dhhr.wv.gov/bph/Documents/MedicalCannabis/MCAB%20Report%20Recommendations
%20FINAL%2002.22.2018.pdf. 
171  Id. 
172  See S. 487, 83d Leg., Reg. Sess. (W. Va. 2018). 
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Bureau.173 Additionally, the amendment would restructure application fees and 
allow the delivery of medical cannabis by a dispensary to qualifying patients.174 
The legislature also considered and rejected a bill which would have 
significantly reduced the stringent restrictions currently placed on permit 
issuance. House Bill 4345 sought to increase the permits available to 50 for 
growers, 50 for processors, and 165 for dispensaries.175 House Bill 4345 also 
would have allowed for the vertical integration of growing, processing, and 
dispensing.176 
Changes to the dry leaf prohibition and permit limitations were both 
supported by the state’s Medical Cannabis Advisory Board.177 In fact, the 
Advisory Board recommended eliminating the limitations on number of permits 
issued entirely.178 The Board noted that while  
[t]he work group is not currently in a position to recommend a
specific number for the increase [in permits] . . . work group
members believe the current numbers are likely too low to
provide for adequate patient access and market viability in light
of . . . interest level that has been indicated thus far.179
The Board also noted that “by increasing the number of permits 
available, a broader cross-section of interested businesses would be able to take 
part in the process allowing for an increase in affordable patient access to 
medical cannabis.”180 Lastly, the Board noted, in furtherance of its concern for 
the economics of medical cannabis in West Virginia, that  
it appears West Virginia is an outlier in prohibiting vertical 
integration among the 29 states that have approved medical 
cannabis laws. . . . [I]t seems that the [prohibition on vertical 
integration] currently provided in the law would make it less 
economically viable for entities to enter into this market and to 
provide an affordable product for patients.181 
The legislature addressed the vertical integration issue in its 2019 session 
by passing House Bill 2079. The bill would have allowed for vertical 
173  Id. 
174  Id. 
175 H.D. 4345, 83d Leg., Reg. Sess. (W. Va. 2018).
176  Id. 
177 W. VA. MED. CANNABIS ADVISORY BD., supra note 170, at 7.
178  Id. (“Recommendation 3.1: Remove limitations on the number of permits the Bureau for 
Public Health may issue for growers, processors, and dispensaries.”). 
179  Id. 
180  Id. (emphasis added). 
181  Id. at 7–8. 
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integration—one person could hold any combination of grower, processor, and 
dispensary permits. The bill was purportedly an effort to attract medical cannabis 
businesses to West Virginia.182 The bill also allowed for chronic pain patients to 
use medical marijuana without having to try an opioid first.183 The legislature 
also passed House Bill 2538 in its 2019 session, which allows credit unions to 
accept medical cannabis revenue.184 But the legislature did not amend restrictions 
on the forms of cannabis that patients can use. 
IV. COMPARISON OF CANNABIS LAW AND POLICY ACROSS THE STATES
West Virginia stands out among the Appalachian states as one of four 
states with a comprehensive medical cannabis program.185 Maryland, 
Pennsylvania, and Ohio also have comprehensive programs, while the rest of the 
Appalachian states allow CBD or low-THC medical cannabis products.186 Like 
West Virginia, Ohio’s strict regulations surrounding medical cannabis led to 
speculation on the potentially high cost of patient participation in the program.187 
Ohio’s $472 average per ounce price of medical cannabis essentially affirmed 
the accuracy of such speculation.188 This Part will attempt to analyze regulations 
and medical cannabis pricing because in many cases pricing could present a 
significant barrier for patients attempting to enter the market.189 However, it must 
be noted that in some jurisdictions’ patient reporting may have to be relied upon 
for price data. Further, estimating dosage is a significant factor when estimating 
how much a patient may spend on medical cannabis, but medical cannabis users 
182  Erin Beck, Bill to Bring Medical Marijuana Businesses to West Virginia Heads to Governor, 
REG.-HERALD (Beckley, W. Va.) (Mar. 9, 2019), https://www.register-
herald.com/news/state_region/bill-to-bring-medical-marijuana-businesses-to-west-virginia-
heads/article_d51a6aaa-2ca1-59c8-bc67-2df4164b444c.html. Delegate Cindy Lavender-Bowe 
explained, “I signed onto the bill because I want to make medical marijuana available ASAP in 
West Virginia to give patients the relief they need.” Id. Delegate Mike Pushkin further stated the 
bill is “the biggest jobs-creating bill that we have this session.” Id. 
183  Id. 
184  Id. 
185  State Medical Marijuana Laws, supra note 5. 
186  Id. 
 187  See Bill Hormann, What to Know About Ohio’s Medical Marijuana Program, 13ABC 
WTVG TV (Oct. 20, 2018, 2:55 PM), https://www.13abc.com/content/news/What-to-know-about-
Ohios-medical-marijuana-program-498111601.html (“[R]ules includ[ing] packaging each daily 
dose separately . . . will drive up prices . . . .”). 
188  See Jackie Borchardt, Why Aren’t Ohioans Rushing to Buy Medical Marijuana?, 
CINCINNATI ENQUIRER (Mar. 25, 2019, 10:11 PM), 
https://www.cincinnati.com/story/news/2019/03/25/why-arent-ohioans-rushing-buy-medical-
marijuana/3205803002/. 
189  See W. VA. MED. CANNABIS ADVISORY BD., supra note 170, at 8. 
2019] FORBIDDEN FLOWER 279 
can have substantially different dosage needs190 and dosage is most often 
discussed in terms of grams of dried flower, which is prohibited in West Virginia. 
Maryland does not restrict the dispersion of dry leaf cannabis and allows 
patients to smoke or vaporize on private property.191 Nor does Maryland prohibit 
the vertical integration of cannabis growers, processors, and dispensaries.192 
Maryland has retained criminal penalties for possessing cannabis outside of its 
medical program.193 The law commands the Maryland Commission to “actively 
seek to achieve racial, ethnic, gender, and geographic diversity when licensing 
medical cannabis growers.”194 The Commission is empowered to license as many 
growers as is necessary to meet demand, but was initially limited to 15 licensed 
growers.195 Maryland law does not require the presence of a licensed physician 
onsite. 
The Baltimore Sun estimates that 3.5 grams of Maryland medical 
cannabis (one eighth of an ounce) costs about $50–$60.196 The same amount is 
estimated to cost an average of $40 throughout the national market.197 However, 
patients have reported prices up to $84 per 3.5 grams.198 The estimated Maryland 
190  See Dustin Sulak, A Physician’s Perspective on Optimal Cannabis Dosing, LEAFLY (Feb.
26, 2018), https://www.leafly.com/news/health/a-physicians-perspective-on-optimal-cannabis-
dosing (describing the unusually large dosing-range for medical cannabis and describing the lowest 
therapeutic dose as optimal); see also Dosing and Delivery of CanniMed Medical Cannabis, 
CANNIMED, https://www.cannimed.ca/pages/dosing-and-delivery (last visited Sept. 9, 2019). A 
Canadian medical cannabis company (responsible for the first sale of medical cannabis in the 
country in 2001 through a deal with the Canadian government) suggests that the average medical 
dose per day is 1–3 grams of dried flower and that 0.78 grams of dried flower is equivalent to 
approximately 60 mL of (this particular company’s) oil. Id. 
191  See MD. CODE ANN., HEALTH–GEN. § 13-3314 (West 2019). 
192  Id. § 13-3314(e). 
193  See id. § 13-3313(b)(1). 
194 Id. § 13-3306(a)(9)(i)(1). 
 195  See DEP’T OF LEGISLATIVE SERVS., FISCAL AND POLICY NOTE, S. 37, 2018 Gen. Assemb., 
Reg. Sess., at 5 (Md. 2018); see also Larisa E. Bolivar, Medical Cannabis Policy in Maryland: 
Proposed Number of Cannabis Grow Licenses Will Not Meet Demand, CANNABIS CONSUMERS 
COALITION (Jan. 19, 2016), https://www.cannabisconsumer.org/medical-cannabis-policy-in-
maryland-proposed-number-of-cannabis-grow-licenses-will-not-meet-demand.html (predicting 
that 15 licenses was “far from sufficient” to meet consumer demand). 
196  Sarah Meehan, FAQ: What You Need to Know About Medical Marijuana in Maryland, 
BALT. SUN (Mar. 20, 2018, 5:30 PM), https://www.baltimoresun.com/health/marijuana/bs-md-
medical-marijuana-faq-20171207-story.html. 
197  Priceonomics, Here’s How Much Marijuana Costs in the United States vs Canada, FORBES 
(May 18, 2018, 12:52 PM), https://www.forbes.com/sites/priceonomics/2018/05/18/heres-how-
much-marijuana-costs-in-the-united-states-vs-canada/#764179bf538a. 
198  See Reviews of Allegany Medical Marijuana Dispensary, GOOGLE, 
https://www.google.com (last visited Sept. 9, 2019) (search “Allegany Medical Marijuana 
Dispensary,” then click the “Google reviews” hyperlink) (reporting high prices and alleging that 
the owner actually bans patients who post or complain about the price). 
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street cost of similar quality cannabis is about $40.199 Thus, an apparently 
conservative daily dose of 0.5 grams in Maryland could cost consumers 
anywhere from $7.10 to $12. A consumer with higher dosage needs could expect 
to pay three to five times that range, resulting in a potential $60 daily medicine 
bill. 
Pennsylvania’s program has many regulations that are similar to West 
Virginia’s. An exhaustive list of qualifying medical conditions is expressly 
enumerated, and similar to that of West Virginia’s.200 The statute also prohibits 
dispersion of dry leaf cannabis, subject to change as regulations are adopted by 
the department.201 The Department of Health currently allows dry leaf dispersion, 
but only for vaporization.202 Smoking medical cannabis is still prohibited. 
Pennsylvania’s scheme differs from West Virginia’s with respect to its tax 
allocations. The Department of Health receives 55% of the tax revenue created 
by the Act.203 The majority of the funding received by the Department (40%) is 
expended by the Department for operations relating to the Act; the remaining 
15% is dedicated to assisting patients who demonstrate financial need with the 
cost of medical cannabis, as well as costs associated with identification cards and 
background checks.204 The remainder of the fund is divided between the 
Department of Drug and Alcohol Programs (for drug abuse prevention, 
counseling, and treatment services) with 10%, further research related to medical 
cannabis with 30%, and the Pennsylvania Commission on Crime and 
Delinquency with only 5%.205 Pennsylvania does not require the presence of a 
physician at every dispensary location.206 Currently, possession of small amounts 
of cannabis (less than 30 grams) without intent to sell is a misdemeanor 
punishable by up 30 days in jail and a $500 fine.207 
Before the Department of Health began allowing dry leaf form, medical 
cannabis had to be purchased in processed forms such as wax or oil 
199  Maryland Weed Prices, BUDZU, http://budzu.com/prices/usa/maryland (last visited Sept. 9, 
2019) (relying on anonymous user submissions for data). 
200  See 35 PA. STAT. AND CONS. STAT. ANN. § 10231.103 (West 2019). 
201  See id. § 10231.303(b)(3). 
 202  Patients and Caregivers, PA. DEP’T HEALTH, 
https://www.health.pa.gov/topics/programs/Medical%20Marijuana/Pages/Patients.aspx (last 
visited Sept. 9, 2019). 
203  See 35 PA. STAT. AND CONS. STAT. ANN. § 10231.902(c)(1). 
204  See id. 
205  Id. § 10231.902(c)(2)–(4). 
206  See id. § 10231.801(b). 
207  Id. § 780-113(g). 
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concentrates208 for up to $75 per gram.209 The price of dry leaf cannabis after its 
prohibition was lifted is approximately $35 per 3.5 grams.210 
Although California was the first state to recognize medical cannabis in 
1996, Colorado was the first state to develop a regulated commercial market for 
medical cannabis in 2010.211 Prior to the passage of Colorado’s act to regulate 
medical cannabis, the state’s constitution was amended in 1999 to exempt 
caregivers and patients from criminal penalties for engaging in or assisting in the 
use of medical cannabis, without establishing a state licensed and regulated 
market.212 Amendment 64, which legalized recreation marijuana sales, was 
passed in 2012 only two years after the establishment of the regulated medical 
market.213 Possession of less than two ounces of cannabis was decriminalized in 
1975, making such possession punishable by a fine of $100 or less when the 
regulated medical market was established.214 
Colorado’s 2010 act establishing medical cannabis regulations 
significantly contrasts with West Virginia’s approach. Dry leaf and flower sales 
are not prohibited,215 patient cultivation of cannabis plants is expressly 
allowed,216 and local county or municipal governments are able to develop their 
own licensing restrictions in addition to the statewide licensing rules.217 In fact, 
local governments even have the power to prohibit operation of medical cannabis 
facilities, including dispensaries.218 Under the House Bill, up to one million 
208  Concentrates contain higher percentages of THC or CBD, and therefore the estimated 1–3 
gram medical dosing average of flower is not directly applicable. See What You Should Know 
About Marijuana Concentrates/Honey Butane Oil, GET SMART ABOUT DRUGS (Aug. 8, 2018) 
https://www.getsmartaboutdrugs.gov/content/what-you-should-know-about-marijuana-
concentrates-honey-butane-oil. Notably, encouraging concentrates by prohibiting flower may 
actually make finding the optimal lowest therapeutic dose more difficult for patients because the 
product is so much stronger. 
209  Ben Schmitt, How Much Is Medical Marijuana in Pennsylvania? Prices Are Coming into 
Focus, PITT. TRIB.-REV. (Feb. 16, 2018, 2:33 PM), https://triblive.com/news/healthnow/13313069-
74/how-much-is-medical-marijuana-in-pennsylvania-prices-are-coming-into-focus. 
210  David Wenner, Pa. Begins Dry Leaf Medical Marijuana Sales, Reminds Users Not to Smoke 
It, PATRIOT-NEWS (Harrisburg, Pa.) (Aug. 1, 2018), 
https://www.pennlive.com/news/2018/08/pa_begins_dry_leaf_medical_mar.html. (“Terrapin 
Pennsylvania, a grower-processor, said this week that dry leaf will sell for as little as $10 a gram.”). 
211  See H.R. 1284, 67th Gen. Assemb., 2d Reg. Sess. (Colo. 2010). 
212  COLO. CONST. art. XVIII, § 14(2)(b)–(c). 
213  See id. § 16. 
214  COLO. REV. STAT. ANN. § 18-18-406(1) (West 2012) (repealed 2013). 
215  See id. § 25-1.5-106(12) (West 2019). 
 216  See id. § 25-1.5-106(8.5) (“All patients cultivating more than six medical marijuana plants 
for their own medical use are encouraged to register with the state licensing authority’s 
registry . . . .”). 
217  Id. § 25-1.5-106(13.5). 
218  See H.R. 1284, 67th Gen. Assemb., 2d Reg. Sess. (Colo. 2010). 
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dollars in initial tax revenue was “appropriated to the Department of Human 
Services to be used to provide integrated behavioral health services for juveniles 
and adults with substance use disorders and mental health treatment needs who 
are involved with, or at risk of involvement with, the criminal justice system.”219 
Currently, Colorado medical cannabis tax revenues are distributed entirely to a 
public school fund and public school capital construction assistance fund.220 
Colorado’s medical cannabis market, being the first of its kind in the 
United States and given its relatively loose restrictions (when compared to 
subsequent developments east of the Mississippi), provided patients with easier 
access to their medical supply. Prices of medical cannabis in 2011 ranged 
between $25 to $50 dollars per 3.5 grams depending on supply and quality of 
product.221 
Of the 33 states that have established comprehensive medical cannabis 
programs (programs that do allow for medical access to THC products), 11 also 
allow adult recreational use.222 Unsurprisingly, the 11 states allowing adult use 
also permit dry leaf cannabis to be dispensed to medical patients. Of the 
remaining 22 states with a comprehensive medical program, 20 allow dry leaf 
cannabis dispersion in at least some circumstances.223 Louisiana and 
Minnesota224 are the only two states besides West Virginia that have established 
a comprehensive medical cannabis program but retain a blanket prohibition on 
dry leaf dispersion.225 
219  Id. (amending § 39-26-123). 
220  COLO. REV. STAT. ANN. § 39-28.8-305. 
 221  See Walt Hickey, The True Story of the Great Marijuana Crash of 2011, BUS. INSIDER (Sept. 
25, 2013, 8:00 PM), https://www.businessinsider.com/the-great-marijuana-crash-of-2011-2013-9. 
222  See State Medical Marijuana Laws, supra note 5 (Alaska, Washington, Oregon, California, 
Nevada, Colorado, Michigan, Vermont, Maine, Illinois, and Massachusetts). 
223  See id. North Dakota requires a physician recommendation for patient dry leaf access. N.D.
CENT. CODE ANN. § 19-24.1-21(4) (West 2019). Utah prohibits dry leaf dispersion unless it is sold 
in a single dose “blister pack” containing no more than one gram of flower. See UTAH CODE ANN. 
§ 26-61a-502(5)(c) (West 2019). New York and Pennsylvania permit dry leaf dispersion but
prohibit smoking.
224  Some Minnesota patients report that the highly regulated program costs them “hundreds or 
even thousands of dollars a month, none of it covered by insurance.” Cost of Medical Marijuana 
in Minnesota Leads Some to Return to Illegal Sources, GUARDIAN (London) (Sept. 20, 2015, 1:23 
PM), https://www.theguardian.com/us-news/2015/sep/20/cost-of-medical-marijuana-in-
minnesota-leads-some-to-return-to-illegal-sources. 
225  See LA. STAT. ANN. § 40:1046 (West 2019); see also Overview of the Louisiana Therapeutic 
Marijuana Act, MARIJUANA POL’Y PROJECT, https://www.mpp.org/states/louisiana/overview-of-
louisianas-medical-cannabis-law/ (last visited Sept. 9, 2019). Louisiana appears unique in that it 
only allows state universities to grow medical cannabis. See General Information About the 
Minnesota Medical Cannabis Program, MINN. DEP’T HEALTH, 
https://www.health.state.mn.us/people/cannabis/about/factsheet.html (last visited Sept. 9, 2019). 
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V. INCREASING THE EFFICACY OF THE ACT BY ALLOWING DRY LEAF
AND REDUCING UNNECESSARY RESTRICTIONS 
Governor Jim Justice described West Virginia’s Medical Cannabis Act 
as a compassionate effort to “help our neighbors who are struggling with 
illness.”226 Given the capacity of medical cannabis to significantly aid our 
struggling neighbors, this Author agrees. However, there are remaining policy 
considerations which could further aid chronically ill West Virginians by 
reducing market barriers, as well as provide the rest of the state with tangential 
benefits. Additionally, the state should consider how a robust cannabis 
marketplace can help generate useful revenue. 
A. Current Restrictions May Price West Virginia Patients Out of the
Market; Loosening Restrictions and Allowing Dry Leaf Cannabis Will
Help Patients Access Treatment
West Virginia’s medical cannabis laws are some of the strictest in the 
country. West Virginia appears to be unique among states recognizing medical 
cannabis in its requirement to have a physician onsite during dispensary hours of 
operation. Further, its prohibition on dry leaf material is a small minority rule 
among the states with operational medical cannabis programs. These factors, 
combined with strict limitations on the number of growing licenses available, 
may operate to reduce supply and increase prices such that many or most West 
Virginian patients simply cannot afford their medicine. 
West Virginia’s relatively conservative policies behind the Medical 
Cannabis Act are indicative of the “fear” and “mystery”227 that has historically 
surrounded the cannabis plant. The state’s concerns regarding potential cannabis 
misuse and teen use are not illegitimate concerns and are likely fueled in part by 
the havoc opioids have wreaked within the state. However, a holistic review of 
the data suggests that while a certain amount of legislative caution is warranted, 
the most stringent restrictions are unnecessary to prevent cannabis misuse, traffic 
accident increases, and teen use increases. 
As described in Part III, medical cannabis prices have a very wide range 
and are sensitive to policies operating within the market. In order to fully provide 
compassionate use options to chronically ill West Virginians, the state should 
seriously consider the Medical Cannabis Advisory Board’s recommendations 
226  See Press Release, W. Va. Office of the Governor, Justice Signs Medical Cannabis Bill into 
Law (Apr. 19, 2017), https://governor.wv.gov/News/press-releases/2017/Pages/Justice-Signs-
Medical-Cannabis-Bill-Into-Law.aspx. 
227  See Zuckerman, supra note 38. In reference to the amendment restricting available forms, 
Judiciary Chairman John Shott said, “We can basically prevent its abuse, and at the same time 
provide help to people who need it.” Kalea Gunderson, Amendment to West Virginia Medical 
Marijuana Bill Restricts Uses, EYEWITNESS NEWS WCHS TV (Apr. 3, 2017), 
https://wchstv.com/news/local/amendment-to-wv-medical-cannabis-act-restricts-marijuana-uses. 
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with respect to increasing patients’ potential to access medical cannabis. 
Otherwise, patients may be unnecessarily foreclosed from trying a physician 
recommended medicine, or worse, encouraged to enter the ever-present black 
market. 
Fortunately, it seems that the legislature realized that an onsite 
physician’s services could be easily replaced by mandatory inserts and labeling 
that provide patients with health and safety information.228 This should 
significantly reduce dispensary operating costs, thus reducing the price of 
medical cannabis products. Further, prohibiting dry leaf dispersion is likely 
unnecessary and to some degree counter-intuitive. For instance, if West 
Virginia’s policies are reflective of concerns over the drug’s potential misuse, 
then why would West Virginia disallow the most natural form of the medicine 
and encourage the use of processed extracts that are generally significantly more 
potent?229 This policy choice is especially questionable given that prohibiting dry 
leaf and requiring processed products will likely increase potential incentive for 
diversion into the black market. If processed products are valued higher, and less 
available in the black market than dry leaf, it follows that the economic 
motivation for diversion will be stronger for concentrated cannabis products. 
Requiring cannabis to be processed before being sold will logically serve 
to increase product price. Presumably West Virginia does not want to encourage 
smoking among chronically ill patients, but other states allow dry leaf while still 
prohibiting smoking. Further, there are some scenarios where patients may not 
even be able to orally ingest medicine such as late-stage chemotherapy patients. 
In such scenarios, a more flexible rule, such as North Dakota’s, which would at 
least allow for the dispersion of dry leaf cannabis to patients that have real need 
(medical or financial) for vaporization (as recognized by a physician) would be 
optimal. Lastly, given West Virginia’s high cancer and opioid prescription rates, 
the demand for medical cannabis could be significant. However, as the Medical 
Cannabis Advisory Board points out, the limited number of growers, processors, 
and dispensaries may not be able to produce supply to meet the demand, thus 
potentially further increasing the price of medical cannabis products. 
228  For a comprehensive example of labeling requirements which are aimed at warning and 
informing patients, see OR. LIQUOR CONTROL COMM’N, PACKAGING AND LABELING GUIDE FOR
MEDICAL AND RECREATIONAL MARIJUANA – VERSION 4.0 (2018), 
https://www.oregon.gov/olcc/marijuana/Documents/Packaging_Labeling/PackagingandLabeling
Guide.pdf. 
229  See supra text accompanying note 208. 
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B. Increasing the Efficacy of the Medical Cannabis Act and Deprioritizing
Criminal Law Enforcement Spending Would Be Economically Beneficial
to West Virginia
Increasing patient access can create a robust marketplace which provides 
West Virginia residents with new opportunities for meaningful employment. 
Cannabis growing, processing, and dispensing is a labor-intensive industry 
which has significant economic impact in areas that allow it.230 
Tax revenue is one the most frequently recognized and cited benefits to 
establishing a regulated cannabis market, medical or recreational. Yet West 
Virginia’s Medical Cannabis Act provides the public with little to no benefit by 
failing to distribute any medical cannabis tax revenue into publicly useful funds, 
such as Colorado does with its public-school funds.231 Instead, the tax revenue is 
used to further enforce criminal prohibition which has largely been unsuccessful 
throughout the nation. 
Prioritizing criminal law enforcement is further evidence of policy 
choices that are reflective of outdated fears surrounding cannabis. When 
considering how to prioritize spending, the state should rely not on “intuitions”232 
about the plant’s dangers, but rather the data available. Concerns over traffic 
safety appear to be largely overblown.233 Increases in money and transient 
population associated with cannabis within legal states tend to explain crime rate 
increases better than the cannabis plant’s psychoactive effect.234 Teenage use is 
a real concern, but criminalization seems an inadequate solution to the problem 
because it fails to deter use.235 
Further, with so many states and countries drastically reforming 
cannabis laws in 2018, and the media aggressively covering the reform, exposure 
to cannabis information is higher than ever. The year 2019 is predicted to follow 
the same trajectory. In an environment where access and exposure to cannabis 
information are ballooning, attempting to maintain any “fear” and “mystery” 
surrounding cannabis through criminalization is an antiquated notion of 
Appalachian isolationism. The public’s perception of harm has already decreased 
230  See supra Part II. 
231  See COLO. REV. STAT. ANN. § 39-28.8-305 (West 2019). 
232  See supra text accompanying note 38. 
233  See supra text accompanying note 65. 
234  See McLean & Weisfeldt, supra note 70. 
 235  Of the two strongest factors for predicting teen use, access and perception of harm, the state 
has the best chance at controlling access. Continued criminalization will likely do little to alter 
teens’ perception of harm, especially when compared to the impact the media has on teens’ 
perceptions. Access doesn’t appear to be greatly impacted by criminalization, either, given the fact 
that stricter cannabis laws have not reduced cannabis-related charges. However, teenage access 
could be restricted by replacing the black market with a robust but tightly regulated market that 
could ensure cannabis suppliers within the community only sold to those with identification who 
are over 21. 
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dramatically compared to decades ago,236 and the current national trends point 
towards further social acceptance throughout the country.237 This will surely 
impact West Virginian’s perceptions as well. Further, in the near future West 
Virginians may have the opportunity to purchase legal cannabis in a bordering 
state.238 Given the current environment, spending the Act’s revenue on 
maintaining legally enforced prohibition seems like an insurmountable uphill 
battle. 
If the Act’s regulations and restrictions were reduced to a degree which 
allows supply to meet demand, and product prices are within a range that the 
consuming population can generally afford, then the medicinal market created 
by the Act could help fund the public teacher pay raise that is recommended by 
the West Virginia Center on Budget and Policy as a tool to combat the state’s 
economic status.239 Alternatively, West Virginia could follow the lead of 
Pennsylvania’s medical cannabis program which funds alcohol and drug abuse 
prevention programs at a higher rate than traditional law enforcement 
mechanisms. Regardless of the route, West Virginia has the opportunity to 
increase the public’s tangential benefits by prioritizing public use funding over 
continuing the current criminal law enforcement status quo. 
VI. CONCLUSION
The Medical Cannabis Act grants patients like Rusty Williams who are 
chronically or terminally ill access to carefully restricted medical cannabis. 
Medical cannabis is a promising alternative treatment to many of the chronic 
ailments afflicting West Virginians. However, the tight regulations stemming 
236  The internet has been one of reform advocates’ greatest tools for releasing data and 
countering old perceptions. See DEANGELO, supra note 10, at 168. 
237  Jolene Forma, senior staff attorney at the Drug Policy Alliance told Newsweek, “In 2019, I 
think we can expect to see more of the same type of change, but maybe at a more rapid pace.” 
Alexandra Hutzler, Marijuana Legalization 2019: Which States Will Consider Legal Weed in Year 
Experts Predict Will Be ‘Real Game-Changer’, NEWSWEEK (Jan. 1, 2019, 8:10 AM), 
https://www.newsweek.com/which-states-legalization-marijuana-2019-1275736 (“The train has 
left the station. Americans of all political affiliations and almost all demographics support 
marijuana legalization.”). 
238  Maryland lawmakers claim legalizing cannabis is on the agenda for the new year’s 
legislative session. Kate Ryan, Legalizing Marijuana, Banning ‘Ghost Guns’ on To-Do List for 
Md. Lawmakers, WTOP-FM (Jan 1, 2019, 6:00 PM), 
https://wtop.com/maryland/2019/01/maryland-legislative-session-starts-in-one-week/. 
Pennsylvania Governor Tom Wolf, previously opposed to legalization, “now says that he’s ready 
to take a serious look at the issue [and] also supports moving ahead immediately with less far-
reaching moves to decriminalize cannabis possession.” Tom Angell, These States Are Most Likely 
to Legalize Marijuana in 2019, FORBES (Dec. 26, 2018, 2:11 PM), 
https://www.forbes.com/sites/tomangell/2018/12/26/these-states-are-most-likely-to-legalize-
marijuana-in-2019/. 
239  See WORKING WEST VIRGINIA, supra note 113. 
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from outdated perceptions will likely serve to make medical cannabis 
inaccessible to at least some West Virginian patients and could potentially create 
an unnecessary financial burden for many more. These concerns would likely be 
reduced by adopting the Medical Cannabis Advisory Board’s recommendations, 
following the majority of other states by allowing dry leaf dispersion, increasing 
available permits, and lifting the onsite physician requirement for dispensaries. 
Easing the restrictions and creating a more robust medical cannabis market could 
also serve the rest of the population by creating a new source of public use 
revenue if criminal prohibition is de-prioritized by the state. A review of 
outcomes in states with robust medical or recreational marketplaces does not 
support the need for regulations as tight as West Virginia’s. Instead, the benefits 
of creating a robust marketplace appear to consistently outweigh costs, 
explaining the incredible rate of cannabis reform throughout the nation.
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